EXHIBIT 99.1

PRESS RELEASE CONTACT:  MICHAEL SENKEN
PHONE:  (770) 651-9100

MIMEDX ANNOUNCES RECORD 2013 RESULTS


COMPANY INCREASES SALES FORCE BY 45% SINCE FIRST OF THIS YEAR


Marietta, Georgia, February 26, 2014
(PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2013.

Highlights of 2013 results include:
· 2013 Revenue more than doubling over prior year
· The 9th consecutive quarter of meeting or exceeding revenue guidance and the 8th consecutive quarter of positive Adjusted EBITDA*
· Cash Flow from Operations Positive in Q3 and Q4
· 2013 Adjusted EBITDA increasing by more than $3 million over prior year
· Raising over $36 million in Q4 to fund growth
· Receiving reimbursement coverage from 6 of 8 Medicare Administrative Contractors in 2013 and the 7th in January of 2014
· Adding 43 direct sales professionals in 2013 and an additional 34 in first two months of 2014

Full Year and Fourth Quarter 2013 Results
The Company recorded record revenue for the year ended December 31, 2013, of $59.2 million, an increase of 119% over 2012 revenue of $27.1 million. The Company’s gross margins for the year ended December 31, 2013, were 84% as compared to 81% in 2012.  Earnings before interest, taxes, depreciation, amortization, share-based compensation and a non-cash impairment charge (Adjusted EBITDA*) for the year ended December 31, 2013, were $5.5 million, a $3.1 million  or 128% improvement, as compared to the Adjusted EBITDA*  of $2.4 million for 2012. The Net Loss for the year ended December 31, 2013, was $4.1 million, as compared to the Net Loss of $7.7 million in the prior year.

The Company recorded record revenue for the fourth quarter of 2013 of $18.0 million, an increase of 71% over 2012 fourth quarter revenue of $10.5 million. The Company’s gross margins for the quarter ended December 31, 2013 were 83% as compared to 84% in the fourth quarter of 2012.  Adjusted EBITDA* for the quarter ended December 31, 2013 were $1.3 million, a $0.9 million or 207% improvement, as compared to the Adjusted EBITDA* of $0.4 million for the fourth quarter of 2012. The Net Loss for the fourth quarter of 2013 was $1.4 million, as compared to the Net Loss of $1.6 million in the prior year fourth quarter.

Management Commentary on Results
Parker H. “Pete” Petit, Chairman and CEO, said, “We are pleased with our 2013 performance and the value we created for our shareholders during the year. We had strong quarter-over-quarter growth and more than doubled our revenue over 2012. The fourth quarter of 2013 was our ninth consecutive quarter where we met or exceeded our revenue forecast. The fourth quarter was also our eighth consecutive quarter of positive Adjusted EBITDA*. Throughout the year, we continued to produce strong gross margins. We continue to invest heavily in additional clinical trials that are essential in growing our reimbursement coverage and increasing physician interest and education. We have a seasoned executive team that understands the importance of continually balancing quarter-over-quarter EBITDA growth with the necessary investments in sales, clinical studies and organization infrastructure that are essential in producing rapid but stable growth.”

The Company’s 2013 revenue growth was primarily driven by wound care sales. Wound care revenue for the year grew 190% over 2012 and Surgical & Sports Medicine revenue grew 79% over 2012. Bill Taylor, President and COO, stated, “In 2013, we expanded our sales force focused on the commercial sector of the wound care market. This expansion facilitated the tripling of our wound care revenue. During the first two months of 2014, we have undertaken another aggressive stage of expansion of our sales force, and we expect that this initiative will contribute to our continued period-over-period revenue growth. At the end of 2013, we had 76 sales professionals in our sales force. In the first two months of 2014, we added 34 sales professionals to our sales force, bringing the total to 110. The vast majority of the new additions have experience in advanced wound care, and we expect rapid growth in their respective territories. We expect to add another five to ten sales professionals to our sales force by the end of the first quarter of 2014.”

Taylor added, “During the fourth quarter, we again ramped up our R&D expenses in support of our aggressive schedule of clinical and scientific studies.  There will be several studies published in the next few months, and they will assist with our 2014 revenue growth.”

“We have sustained our rapid pace of facilitating the awarding of coverage from the Medicare Administrative Contractors (MACs). We ended 2013 with reimbursement coverage by six of the eight MACs, and recently, we were awarded coverage from another MAC, bringing our current status of Medicare coverage for our EpiFix® allograft to seven of the eight MACs, with coverage in 49 of the 50 states.  The only remaining MAC needed to approve EpiFix coverage is First Coast Service Options (FCSO), whose jurisdiction is the State of Florida. In addition, we recently were awarded coverage from another of the large Blue Cross and Blue Shield plans that covers multiple states and millions of lives. In addition to these coverage awards, we are seeing the results from our numerous clinical studies and trials materialize into a growing number of coverage awards from many of the commercial health plans and state Medicaid programs,” stated Petit. “Maintaining our initiatives focused on these reimbursement approvals is a major priority for MiMedx in 2014.”

Balance Sheet and Cash Flow
As of December 31, 2013, total assets increased by $49.5 million to $84.7 million. Cash on hand as of December 31, 2013, was $44.1 million, an increase of $37.3 million, as compared to $6.8 million as of December 31, 2012.  Cash flow from operating activities for the year was a negative $285,000, as compared to a negative $3.3 million in 2012. In the third quarter of 2013, the Company recorded positive quarterly cash flow from operations for the first time in its history.

Accounts receivable increased to $16.1 million as of December 31, 2013, from $7.7 million as of December 31, 2012. This was largely due to the higher sales volume and the buildup of the Company’s commercial wound care sales. In preparation for increased demand in commercial wound care sales in early 2014, inventory increased by $858,000 to $3.9 million. Total liabilities decreased from $15.2 million as of December 31, 2012, to $11.1 million as of December 31, 2013. The decline in total liabilities was primarily the result of conversion of the senior secured promissory notes and the final payout of the earn-out related to the acquisition of Surgical Biologics. Stockholders’ equity increased by $53.6 million to $73.6 million as of the end of 2013.

GAAP Earnings
The Company recorded a Net Loss of $4.1 million for the year ended December 31, 2013, or $0.04 per diluted common share, as compared to a Net Loss of $7.7 million, or $0.09 per diluted common share, for the year ended December 31, 2012. During the fourth quarter, the Company chose to discontinue the HydroFix® product line. This action resulted in an impairment charge of approximately $368,000 related to licenses. This item is included in the Statement of Operations as of December 31, 2013. The Company recorded a Net Loss of $1.4 million, or $0.01 per diluted common share, for the quarter ended December 31, 2013, as compared to the Net Loss of $1.6 million, or $0.02 per diluted common share, recorded for the quarter ended December 31, 2012. The Net Loss includes a total of $2.7 million in non-cash related expenses, including $1.9 million in share-based compensation expense, $260,000 in amortization of intangibles, and $223,000 in depreciation expense. The Net Loss for the same period in 2012 included $2.0 million in non-cash related charges.

Full year 2013 Research and Development expenses were $4.8 million, or 8% of Net Sales, as compared to $2.9 million, or 11% of Net Sales, for the same period in 2012. For the fourth quarter of 2013, Research and Development expenses were $1.4 million or 8% of Net Sales, an increase of $249,000 over the fourth quarter of 2012 expenses, due to the accelerated investment in clinical trials for reimbursement purposes.

Selling, general and administrative (SG&A) expenses for the year ended December 31, 2013, were $46.2 million, or 78% of Net Sales, as compared to $19.6 million, or 72% of Net Sales for the year ended December 31, 2012. SG&A expenses for the fourth quarter of 2013 were $14.3 million, or 79% of Net Sales, a $6.1 million increase over fourth quarter of 2012 expenses of $8.1 million.  Increases in SG&A were due to the continuation of the buildup of the Company’s direct sales force in the government accounts and commercial accounts sales channels. The addition of key management and infrastructure-related resources necessary to support the Company’s growth, including key resources in support of our reimbursement activities, also impacted the increase in SG&A expenses.

Use of non-GAAP financial measures
Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles (GAAP). These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted EBITDA* is earnings before interest, taxes, depreciation, amortization, share-based compensation, non-cash impairment and earn-out liability charges. For a reconciliation of this non-GAAP financial measure to the most directly comparable financial measure, see accompanying table to this release. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Revenue Breakdown
The Company distinguishes its revenue breakdown among three primary regenerative medicine specialties, “Wound Care,” “Surgical & Sports Medicine,” and “Other,” and reports its revenue in these categories.  Revenue for the Company’s EpiFix® grafts comprises the Wound Care category. The Company’s Surgical & Sports Medicine specialty is comprised of its injectable, orthopedic and surgical applications for its AmnioFix® grafts. The “Other” category of the MiMedx regenerative medicine specialties includes the Company’s tissue revenue from its dental and ophthalmic applications and products from its HydroFix® technology. In 2013, Wound Care represented 55% of full year revenue, Surgical & Sports Medicine represented 40% of full year revenue and 5% of revenue was attributed to the “Other” revenue category.

The Company also provides a revenue breakdown in terms of customer type, distinguishing between government and commercial accounts. Government accounts include the Veterans Administration as well as the Department of Defense and Indian Health Services. Commercial sales include sales through distributors, OEM sales and direct sales to non-government accounts. For the year ended December 31, 2013, Government sales represented 57% and Commercial sales represented 43% of revenue.

Outlook for First Quarter and Full Year 2014
The Company reaffirmed its previously communicated guidance for full year 2014 in which revenue is forecasted to be in the range of $90 million to $110 million. As with 2013, the Company will update this forecast on a quarter-by-quarter basis. In 2013, the lower estimate of $50 million was raised by the Company each quarter until the original lower end estimate of $50 million reached $57.3 million. At this point, the Company estimates first quarter of 2014 revenue will be in the range of $18 million to $19.5 million.

Earnings Call
MiMedx management will host a live broadcast of its first quarter results conference call on Wednesday, February 26, 2014, beginning at 10:30 a.m. eastern time.  A listen-only simulcast of the MiMedx Group conference call will be available online at the Company’s website at www.mimedx.com or at www.earnings.com.  A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.  The replay can also be found on the Company’s website at www.mimedx.com or at www.earnings.com.

About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 200,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, the impact of clinical trials on reimbursement coverage and physician education and interest in our products, the effect of expansion of the sales force on period-over-period revenue growth, the expectation for rapid sales growth in the territories assigned to new sales professionals, the ability to add additional sales professionals in the time periods anticipated, the potential for coverage by FCSO in the near term, and the Company’s projected revenues for first quarter and full year 2014. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Company’s clinical trials may not have the desired effect on reimbursement coverage or increased physician education and interest in our products , the expansion of the sales force might not have the expected effect on revenue growth in any particular territory or overall, the Company may not be successful in further expanding its sales force in the time periods anticipated, FCSO may not provide coverage for EpiFix soon or at all, the Company may not achieve its projected revenue goals, and the risk factors detailed from time to time in the Company’s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012, and the Company’s Forms 10-Q filed in 2013. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company’s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

 
 
Years Ended December 31,
 
 
 
2013
   
2012
   
2011
 
 
 
   
   
 
Net sales
 
$
59,180,734
   
$
27,053,773
   
$
7,760,446
 
Cost of sales
   
9,328,114
     
5,188,378
     
3,357,909
 
Gross margin
   
49,852,620
     
21,865,395
     
4,402,537
 
 
                       
Operating expenses:
                       
Research and development expenses
   
4,843,457
     
2,884,546
     
2,976,313
 
Selling, general and administrative expenses
   
46,225,657
     
19,590,446
     
9,845,529
 
Impairment of intangible assets
   
368,102
     
1,798,495
     
-
 
Fair value adjustment of earn-out liability
   
-
     
1,567,050
     
5,803
 
Amortization of intangible assets
   
1,053,971
     
1,380,241
     
1,335,908
 
 
                       
Operating income (loss)
   
(2,638,567
)
   
(5,355,383
)
   
(9,761,016
)
 
                       
Other income (expense), net
                       
Amortization of debt discount
   
(1,328,439
)
   
(1,714,101
)
   
(315,152
)
Interest expense, net
   
(45,233
)
   
(592,892
)
   
(117,818
)
 
                       
Income (loss) before income tax provision
   
(4,012,239
)
   
(7,662,376
)
   
(10,193,986
)
Income tax provision
   
(99,614
)
   
-
     
-
 
 
                       
Net Income (loss)
 
$
(4,111,853
)
 
$
(7,662,376
)
 
$
(10,193,986
)
 
                       
Net income (loss) per common share - basic and diluted
 
$
(0.04
)
 
$
(0.09
)
 
$
(0.14
)
 
           
.
         
Weighted average shares outstanding - basic and diluted
   
96,285,504
     
81,646,295
     
72,450,337
 


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

ASSETS
 
   
 
 
 
   
 
 
 
December 31,
   
December 31,
 
 
 
2013
   
2012
 
 
 
   
 
Current assets:
 
   
 
Cash and cash equivalents
 
$
44,077,751
   
$
6,754,485
 
Accounts receivable, net
   
16,092,836
     
7,653,561
 
Inventory, net
   
3,880,776
     
3,022,784
 
Prepaid expenses
   
1,337,408
     
657,961
 
 
               
Total current assets
   
65,388,771
     
18,088,791
 
 
               
Property and equipment, net of accumulated depreciation
   
4,086,106
     
1,071,625
 
Goodwill
   
4,040,443
     
4,040,443
 
Intangible assets, net of accumulated amortization
   
11,178,573
     
11,911,749
 
Other assets
   
-
     
70,000
 
 
               
Total assets
 
$
84,693,893
   
$
35,182,608
 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
Current liabilities:
               
Accounts payable
 
$
2,490,531
   
$
1,251,684
 
Accrued compensation
   
5,588,811
     
2,753,237
 
Accrued expenses
   
1,405,974
     
990,697
 
Other current liabilities
   
122,551
     
21,583
 
Total current liabilities
   
9,607,867
     
5,017,201
 
 
               
Earn-out liability payable in MiMedx common stock
   
-
     
5,792,330
 
Convertible Senior Secured Promissory Notes, net
   
-
     
4,012,442
 
Other Liabilities
   
1,517,956
     
353,333
 
Total liabilities
   
11,125,823
     
15,175,306
 
 
               
Commitments and contingencies (Note 15)
               
 
               
Stockholders' equity:
               
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding
   
-
     
-
 
Common stock; $.001 par value; 130,000,000 shares authorized; 104,425,614 issued and 104,375,614 outstanding for 2013 and 88,423,169 issued and 88,373,169 outstanding for 2012
   
104,426
     
88,423
 
Additional paid-in capital
   
147,284,219
     
89,627,601
 
Treasury stock (50,000 shares at cost)
   
(25,000
)
   
(25,000
)
Accumulated deficit
   
(73,795,575
)
   
(69,683,722
)
Total stockholders' equity
   
73,568,070
     
20,007,302
 
 
               
Total liabilities and stockholders' equity
 
$
84,693,893
   
$
35,182,608
 


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

 
 
Years Ended December 31,
 
 
 
2013
   
2012
   
2011
 
 
 
   
   
 
Cash flows from operating activities:
 
   
   
 
Net income (loss)
 
$
(4,111,853
)
 
$
(7,662,376
)
 
$
(10,193,986
)
Adjustments to reconcile net income (loss) to net cash from operating activities:
                       
Depreciation
   
637,246
     
465,367
     
446,502
 
Loss on fixed asset disposal
   
36,800
     
-
     
-
 
Amortization of intangible assets
   
1,053,971
     
1,380,241
     
1,335,908
 
Impairment of intangible assets
   
368,102
     
1,798,495
     
-
 
Amortization of debt discount and deferred financing costs
   
1,328,439
     
1,714,101
     
315,152
 
Share-based compensation
   
6,009,176
     
2,538,721
     
1,659,083
 
Change in fair value of earn-out liability
   
-
     
1,567,050
     
5,803
 
Increase (decrease) in cash resulting from changes in:
                       
Accounts receivable
   
(8,439,275
)
   
(5,761,642
)
   
(1,208,456
)
Inventory
   
(857,992
)
   
(2,310,182
)
   
(253,942
)
Prepaid expenses
   
(706,683
)
   
(466,060
)
   
(70,980
)
Other assets
   
70,000
     
96,657
     
(80,375
)
Accounts payable
   
1,208,747
     
(81,112
)
   
732,938
 
Accrued compensation
   
2,835,574
     
2,354,888
     
194,934
 
Accrued expenses
   
352,881
     
605,856
     
328,379
 
Accrued interest
   
(41,641
)
   
387,896
     
107,886
 
Other liabilities
   
(28,969
)
   
40,840
     
16,383
 
Net cash flows from operating activities
   
(285,477
)
   
(3,331,260
)
   
(6,664,771
)
 
                       
Cash  flows from investing activities:
                       
Purchases of equipment
   
(2,336,517
)
   
(636,502
)
   
(486,091
)
Cash paid for acquisition, net of cash acquired of $33,583
   
-
     
-
     
(466,417
)
Proceeds from grant
   
-
     
-
     
250,000
 
Patent application costs
   
(688,897
)
   
-
     
-
 
Net cash flows from investing activities
   
(3,025,414
)
   
(636,502
)
   
(702,508
)
 
                       
Cash flows from financing activities:
                       
Proceeds from exercise of stock options
   
1,981,418
     
1,052,668
     
295,753
 
Proceeds from exercise of warrants
   
2,107,883
     
6,001,063
     
-
 
Proceeds from Senior Secured Promissory Notes
   
-
     
-
     
5,000,000
 
Proceeds from Line of Credit with related party
   
-
     
-
     
1,300,000
 
Proceeds from sale of common stock and warrants and common stock with registration rights, net
   
-
     
-
     
3,730,587
 
Proceeds from secondary offering, net of expenses
   
36,602,306
     
-
     
-
 
Repayment of Line of Credit
   
-
     
-
     
(99,000
)
Repayment of Note Payable
   
-
     
-
     
(88,657
)
Repayment of convertible debt related to acquisition
   
-
     
(427,126
)
   
-
 
Payment of equipment leases
   
(57,450
)
   
(16,116
)
   
-
 
Repurchase of warrants
           
(568
)
   
-
 
Net cash flows from financing activities
   
40,634,157
     
6,609,921
     
10,138,683
 
 
                       
Net change in cash
   
37,323,266
     
2,642,159
     
2,771,404
 
 
                       
Cash and cash equivalents, beginning of period
   
6,754,485
     
4,112,326
     
1,340,922
 
Cash and cash equivalents, end of period
 
$
44,077,751
   
$
6,754,485
   
$
4,112,326
 


MiMedx Group, Inc. and Subsidiaries
 
Non-GAAP Financial Measures and Reconciliation
 
As used herein, “GAAP”, refers to generally accepted accounting principles in the United States.  We use various numerical measures in conference calls, investor meetings and other forums which are or may be considered “Non-GAAP financial measures” under Regulation G.  We have provided below for your reference, supplemental financial disclosure for these measures, including the most directly comparable GAAP measure and an associated reconciliation.
 
Reconciliation of Net Loss to “Adjusted EBITDA” defined as Earnings before Interest, Taxes, Depreciation, Amortization and Share Based Compensation:

 
 
Twelve Months Ended December 31,
 
 
 
2013
   
2012
   
2011
 
Net  Income (loss) (Per GAAP)
 
$
(4,111,853
)
 
$
(7,662,376
)
 
$
(10,193,986
)
 
                       
Add back:
                       
Income Taxes
   
99,614
     
-
     
-
 
 
                       
Financing expense associated with beneficial conversion of note payable issued in conjunction with acquisition
   
-
     
170,509
     
266,991
 
 
                       
Financing expense associated with beneficial conversion of Line of Credit with Related Party
   
-
     
561,202
     
33,254
 
Financing expense associated with beneficial conversion of Senior Secured Promissory Notes
   
1,328,439
     
982,390
     
14,907
 
Other interest expense, net
   
45,233
     
592,892
     
117,818
 
Depreciation Expense
   
637,246
     
465,367
     
446,502
 
Loss on fixed asset disposal
   
36,800
     
-
     
-
 
Amortization Expense
   
1,053,971
     
1,380,241
     
1,335,908
 
Share Based Compensation
   
6,009,176
     
2,538,721
     
1,659,083
 
Impairment of Intangible Assets
   
368,102
     
1,798,495
     
-
 
Fair Value Adjustment of Earn-out Liability
   
-
     
1,567,050
     
5,803
 
Earnings/(Loss) Before Interest, Taxes, Depreciation, Amortization and Share-Based Compensation
 
$
5,466,728
   
$
2,394,491
   
$
(6,313,720
)





The following information was filed by Mimedx Group, Inc. (MDXG) on Wednesday, February 26, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Mimedx Group, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Mimedx Group, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account